Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
351
datasets available to search
ShareScore release 0.9.0
Dataset results
351 results for “empagliflozin”
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT02453555. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
ClinicalTrials.gov study NCT03200860. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
ClinicalTrials.gov study NCT05182840. IPD Sharing: YES. Countries: 29. Publications: 2.
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
ClinicalTrials.gov study NCT02414958. IPD Sharing: Not stated. Countries: 17. Publications: 2.
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT01370005. IPD Sharing: YES. Countries: 12. Publications: 4.
The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.
ClinicalTrials.gov study NCT04342819. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
ClinicalTrials.gov study NCT02580591. IPD Sharing: Not stated. Countries: 24. Publications: 2.
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
ClinicalTrials.gov study NCT05465317. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01734785. IPD Sharing: Not stated. Countries: 11. Publications: 1.
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
ClinicalTrials.gov study NCT01867307. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
ClinicalTrials.gov study NCT02632747. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
ClinicalTrials.gov study NCT01195675. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT02489968. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
ClinicalTrials.gov study NCT01634100. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01289990. IPD Sharing: Not stated. Countries: 19. Publications: 5.
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
ClinicalTrials.gov study NCT01392560. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT01193218. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pre
ClinicalTrials.gov study NCT05282121. IPD Sharing: YES. Countries: 16. Publications: 1.
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
ClinicalTrials.gov study NCT03030222. IPD Sharing: NO. Countries: 1. Publications: 3.
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
ClinicalTrials.gov study NCT01164501. IPD Sharing: Not stated. Countries: 15. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.